Back to all bills
HRES 928119th CongressIn Committee
Affirming support for most-favored-Nation drug pricing for United States patients.
Introduced: Dec 4, 2025
Sponsor: Rep. Dingell, Debbie [D-MI-6] (D-Michigan)
Standard Summary
Comprehensive overview in 1-2 paragraphs
House Resolution 928 affirms support for most‑favored‑nation drug pricing, urging alignment of U.S. prescription drug prices with those of comparable developed nations and backing Medicare price negotiation and market competition.
Key Points
- 1Highlights U.S. high drug spending and price disparities versus other countries.
- 2References executive orders directing price alignment with lowest foreign prices.
- 3Supports Medicare drug price negotiation and price competition.
- 4Calls for patients to pay no more than foreign counterparts for identical drugs.
- 5Reaffirms bipartisan commitment to reducing prescription costs.
Impact Areas
U.S. patients and consumersPharmaceutical manufacturers and pricing strategiesMedicare and federal health programsHealthcare cost containment and taxpayer burden
Generated by openai/gpt-oss-20b:free on Dec 6, 2025